Effect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree^®) in Adults

CONCLUSIONS: Mild-to-severe HI showed minimal impact on viloxazine ER exposure. The single dose of viloxazine ER was well-tolerated with no identified safety concerns.

via https://pubmed.ncbi.nlm.nih.gov/42503060/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20260731011005&v=2.20.0.post5+40e1b98

Post a Comment